Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 10, Pages 2489-2495
Publisher
Springer Nature
Online
2014-04-11
DOI
10.1038/bjc.2014.169
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
- (2013) Alexander M. Menzies et al. EUROPEAN JOURNAL OF CANCER
- Functional Classification of Cellular Proteome Profiles Support the Identification of Drug Resistance Signatures in Melanoma Cells
- (2013) Verena Paulitschke et al. JOURNAL OF PROTEOME RESEARCH
- Functions of S100 Proteins
- (2012) R. Donato et al. CURRENT MOLECULAR MEDICINE
- Proteomic Analysis of Glioma Chemoresistance
- (2012) Kyoungho Suk Current Neuropharmacology
- International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?
- (2012) Friederike Erdmann et al. INTERNATIONAL JOURNAL OF CANCER
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
- (2011) Poulam M. Patel et al. EUROPEAN JOURNAL OF CANCER
- The IL1α-S100A13 Heterotetrameric Complex Structure
- (2011) Sepuru K. Mohan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Protein signatures for survival and recurrence in metastatic melanoma
- (2011) William M. Hardesty et al. Journal of Proteomics
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma
- (2011) T Strub et al. ONCOGENE
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC
- (2010) Christian Busch et al. EUROPEAN JOURNAL OF CANCER
- Effect of Human S100A13 Gene Silencing on FGF-1 Transportation in Human Endothelial Cells
- (2010) Renxian Cao et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- S100A13 is a new angiogenic marker in human melanoma
- (2010) Daniela Massi et al. MODERN PATHOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide
- (2010) C. Kim et al. ONCOLOGIST
- Multidrug Resistance Decreases with Mutations of Melanosomal Regulatory Genes
- (2009) T. Xie et al. CANCER RESEARCH
- Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma
- (2009) C. K. Augustine et al. CLINICAL CANCER RESEARCH
- Novel MITF targets identified using a two-step DNA microarray strategy
- (2008) Keith S. Hoek et al. Pigment Cell & Melanoma Research
- Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines
- (2007) A. Pierce et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now